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ABSTRACT OF THESIS 
 
 
Glioblastoma is one of the most aggressive and invasive cancer with high mortality 
rates and poses several hurdles in the efficient chemotherapeutic intervention. Like other 
cancers, glioma also harbors cancer stem cells (CSCs), which are self-renewable and 
multipotent cells initiating the cancer incidence and exhibiting chemotherapeutic 
resistance and cancer recurrence. Previous study with our platform of microarray showed 
that CD44 is overexpressed in all glioma cancer cell lines analyzed but little expressed in 
the normal adult brain and fetal brain. CD44 is a multifunctional transmembrane 
glycoprotein which is considered as a marker specific to CSCs in various cancers. Since 
the principal ligand of CD44 is hyaluronan acid (HA), which is a major component of 
extracellular matrices, CSC population was thought to be condensed by exploiting HA 
affinity toward CD44.  
In this study, U251MG cells were cultured under non-adherent condition in the 
presence of high molecular weight of hyaluronic acid (HA). The HA dependent spheroid 
forming population was then condensed and transplanted subcutaneously into Balb/c nude 
mouse. The primary cells excised from the resultant tumor were named as U251MG-P1 
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cells, which have been confirmed to express CD44 along with principal pluripotency 
genes, OCT3/4, SOX2, KLF4 and Nanog. U251MG-P1 cells were further characterized 
as CSC.  After confirming the tumorigenicity of U251MG-P1 cells, we concluded that the 
U251MG-P1 was well established to provide a xenograft model of glioblastoma stem cells 
in nude mice. 
Then this model was considered suitable to develop a drug delivery system 
targeting CSCs since U251MG-P1 cells exhibited tumor-initiating capacity while 
retaining the glioblastoma traits. Evaluating the sensitivity to anti-cancer agents, we found 
U251MG-P1 cells were sensitive to doxorubicin with IC50 at 200 nM. Although 
doxorubicin has serious side-effects, establishment of an efficient therapy targeting 
undifferentiated glioblastoma cell population is necessary. We previously designed a 
chlorotoxin peptide fused to human IgG Fc region without hinge sequence (M-CTX-Fc), 
which exhibited a stronger growth inhibitory effect on the glioblastoma cell line A172 
than an original chlorotoxin peptide. Combining these results together, we designed M-
CTX-Fc conjugated liposomes encapsulating doxorubicin and used U251MG-P1 cells as 
the target model in this study. The liposome modified with M-CTX-Fc was designed with 
a diameter of approximately 100–150 nm and showed high encapsulation efficiency, 
adequate loading capacity of anticancer drug, enhanced antitumor effects, demonstrating 
increasing uptake into the cells in vitro; M-CTX-Fc-L-Dox shows great promise in its 
ability to suppress tumor growth in vivo and it could serve as a template for targeted 
delivery of other therapeutics.  
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GENERAL INTRODUCTION 
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1.0 Introducing Glioblastoma and Glioblastoma Stem cells. 
The word “glioma” arise from glial cells. It is a type of tumor that originally from 
brain or spine. Glioma are categorized according to the specific type of cells from which 
its originate and degree of malignancy. World Health Organization (WHO) has been 
assigned glioma as glioblastoma (grade IV) , astrocytoma (grade I-III), oligodendro-
glioma (grade II and III) , and mixed glioma (grade II and III) [1]. Grade I and II gliomas 
are clinically benign or semi benign with long -term survival while grade III and IV are 
malignant and lethal within several years. Among them, Glioblastoma multiforme (GBM) 
is the most aggressive and happened frequently to adult from ages 45-55 and 
predominance in males. The main standard care for patients with GBM consists of 
maximal surgical resection, radiotherapy and adjuvant chemotherapy with temozolomide 
[2]. Although extensive efforts have been done, most malignant glioma often relapse after 
treatments because of their normally diffuse infiltration into the surrounding brain.  
 
1.1 Glioblastoma biomarkers 
 Tumor or cancer biomarker normally consist of wide variety of objects, 
including DNA, mRNA, secreted proteins, cell surface receptor, transcription factors, and 
metabolites, or processes such as apoptosis, angiogenesis or proliferation. They were 
produce either by the tumor itself or by other tissues or cells, in response to the presence 
of tumors or other associated in response to the presence of tumors or other associated 
irritation, like inflammation [3]. By identify the biomarker of cancer will give several 
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advantages such as can help doctors to profile the cancer predisposition, to give clue of 
cancerous stages, early diagnosis and prognosis after treatment and decide which drugs 
and what does it might be most effective to the patients with tumors. 
 
1.1.1 Glial Fibrillary Acidic Protein (GFAP) 
 The common marker associated with glioma is glial fibrillary acidic protein 
(GFAP). It is a member of the cytoskeletal protein family and is widely detected in 
astrooglial cells and neural stem cells [4] . The serum GFAP levels of patients diagnosed 
with glioblastoma multiforme was significantly higher than those of patients with WHO 
grde II or III astrocytomas or of patients with brain metastases [5]. However, GFAP does 
not provide a better staining for distinguishing histologic subtypes of high grade glioma 
by immunohistochemistry [6]  
 
1.1.2  Human cartilage glycoprotein-39 (YKL-40 or CHI3L1) 
A secreted human cartilage glycoprotein -39 (YKL-40 or CHI3L1) also known as 
diagnostic markers for glioma. High level of YKL-40 also associated as a serum marker 
for several numbers of cancers including breast [7] , colorectal [8] and ovarian cancer [9]. 
Although it is often over-expressed in epithelial cancers, previous study has been 
suggested that YKL-40 is a marker associated with poorer clinical outcomes and a 
genetically defined histological subgroup of high grades gliomas.  It is reporter having 
stronger marker for immunohistochemistry, provided a better class distinction compared 
6 
 
to GFAP marker. Alternatively, the combination of YKL-40 and GFAP will enhanced the 
diagnostic accuracy [6]. Moreover, the YKL-40 was also implicated as an important 
marker of radiation therapeutic response and genetic subtype in glioblastomas [10]. In the 
later year, except for YKL-40, matrix metalloproteinase-9 (MMP-9) protein was also 
highly differentially expressed in malignant gliomas. ELISA analysis from serum samples 
from patients with gliomas indicated that the both biomarker correlated with the patient’s 
radiographic status and survival. Therefore, YKL-40 and MMP-9 may be used as a 
biomarker in glioma patients [11].  
 
1.2 Glioblastoma Stem Cells 
 
1.2.1 Concept of cancer stem cells 
 
 It is well believed that cancer tissues are heterogenous. It composed of various 
types of cells with different morphology and clinical phenotypes. This different has been 
explained by the stochastic clonal evolution model [12]. According to this model, all 
tumor cells should have low but inheritable ability to form tumor. However, another 
concept (hierarchy model) has been proposed, which shows that only a rare stem cell 
population called as cancer stem cells (CSC) has high ability to proliferate [13]. Similar 
characteristic with to normal stem cells, CSC having high ability to self-renew and 
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differentiate into multiple type of progenies. Contrarily with normal stem cells, CSCs can 
proliferate uncontrollably to propagate tumor cells.  
 Stochastic clonal evolution model; According to this model, tumor initiation 
occurs in the individual cells receiving multiple mutations, and cells having an 
advantageous mutation of growth can clonally proliferate and selectively occupy an entire 
tumor. During tumor progression, genetic instability yields the additional mutations by 
chance, resulting in a diversity of genome and cell characteristics, such as being invasive, 
metastatic and therapy-resistant. The adaptation to surrounding microenvironment is also 
a determinant of the selection. Standing on this concept, all the tumor cells should have 
low but inheritable ability to form tumors, therefore, the rational targets for cancer therapy 
is most or all of tumor cells. (Figure 1) 
Hierarchy model; Cells may acquire various genetic and epigenetic mutations that 
confer stem-like characteristics, and divide to produce its identical copy (self-renewal) 
and progenies terminally growth-arrested (differentiation). Such a hierarchy in a stem cell 
division manner results in cellular diversity of a rare stem cell and most of multiple types 
of progenies (Figure 1) 
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Figure 1: Clonal evolution model and hierarchy model (Tabu et al.,2011). 
 
1.2.2 Methods to isolate cancer stem cells 
 
1.2.2.1 Sphere formation assay 
 
 In the first place, the sphere formation assay was first developed to characterize 
the behaviour of neural stem cells [14]. Cells were cultured into low attachment dish in 
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serum free media supplemented with mitogen (epidermal growth factor and fibroblast 
growth factor for neural stem cells). In those condition, only cancer stem cell will survive 
by forming floating spherical cell clusters while differentiated cells will be died. Therefore, 
the number and diameter of spheres are thought to reflect the frequency of stem cells and 
mitotic activity of a single stem cell within the examined population, respectively. When 
a 1st sphere is picked up, re-dissociated into single cells, and re-cultured, the generated 
secondary spheres indicating the sustained self-renewal potential of a true stem cell. 
However, sphere formation assay has several limition for isolation of some types of CSCs 
in which condition of sphere assay for normal stem cells is unestablished, it is uncertain 
if they have significance for stem cell activity in the tissues. 
 
1.2.2.2 Hoechst 33342 dye effluxing side population (SP) 
 
 Hoechst 33342 is a fluorescent dye and also one of dye transport-based assay. The 
dye becomes fluorescent after entering the cell and binds to the AT-rich regions of DNA. 
In most cases , stem cells are not stained due to high expression of ABC transporter family 
genes to efflux this dye. Human fetal neural stem/progenitor cells express high levels of 
multidrug resistance 1 (MDR1, also known as ABCB1, P-gp) gene and ATP-binding 
cassette sub-family G member 2 (ABCG2, also known as Bcrp), and these transporters 
have important roles in normal physiology on the active efflux of xenobiotics from cell 
body, protecting cells from cytotoxic agents. 
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Abstract 
 
 
Glioblastoma is one of the most aggresive cancer with high mortality rates and poses 
several hurdles in the efficient chemotherapeutic intervention. Similar to other cancers, 
glioma also haarbors CSCs, that are self renewable, multipotent cells, which innitiate the 
cancer incidence, chemotherapeutic resistance and cancer recurrence. The 
microenviroment regulation in the brain tumor and metastasis involves the cooperative 
interaction between HA and CD44. CD44, being a multifaceted transmembrane 
glycoprotein by itself, or in combinatiom with several other cell surface receptors, has 
been used as a marker for CSC isolation. We established both adherent and non adherent 
culture of U251MG cells by treating with high molecular weight HA. Further these cells 
were transplanted subcutenously in Balb/c mouse for the generation of the xenograft 
model for the cancer stem cell. The tumor was further characterized for the establishment 
of the working model for molecular targeting studies of cancer stem cells. Here we showed 
the enrichment of the CD44 expressing population of glioblastoma cells by induction with 
hyaluronic acid. The non-adherent culture spheroids of U251MG cells showed up 
regulation in the CD44 expression along with aberrant activation of principal pluripotency 
genes OCT3/4, SOX2, KLF4 and Nanog. Using the HA-treated spheroid, we established 
an experimental xenograft mouse model with high angiogenesis enhanced tumor-initiating 
capacity while retaining the glioblastoma traits.We characterized a mouse model of 
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U251MG cells which could be a promising model system to study the molecular targeting 
approaches against CSCs in glioblastoma. 
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1.0 Introduction 
 
Glioblastoma multiforme is the one of the most malignant cancer affecting the brain 
making them one of the incurable cancers with a survival rate of 5%. Several studies have 
shed light on the cytogenetic, molecular and epigenetics alterations during its incidence 
and have characterized the tumor to its molecular level [1]. Histopathological attributes 
have helped in the classifying gliomas into two broad lineages: astrocytoma and 
ologodendroma and four grades (I-IV) of which the grade I and II corresponds to the low-
grade glioma and III and IV correspond to the high- grade gliomas [2]. Glioblastoma cells 
are non-invasive outside the brain partly because of the effective blood brain barrier and 
the multitude of the complex microenviroment which it requires for the metastasis [3]. 
With the progression of the tumor metastatic cells uses the neovascularization for the 
spread of cancer and the blood- brain barrier changes to a blood-tumor barrier. 
Considering the microenvironment in the brain and its relative complexity in targeting the 
blood-tumor barrier are less receptive to chemotherapeutic intervention [4]. Glioma, like 
other cancers, are highly heterogenous and shows hierarchy in their progression with the 
apex being the Cancer Stem Cells (CSCs) which repopulates the whole of the tumor. The 
CSCs are believed to be the primordial reason for the recurrence and reinstatement of the 
tumor after chemotherapeutic intervention and surgery as they are radiation and 
chemotherapeutics resistant [5]. The perpetual self- renewability of the CSC is a complex 
process, which is mediated by the cellular and soluble attributes of the tumor 
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microenviroment which includes the extracellular matrix, mesenchymal cells, endothelial 
cells and secretory molecules comprising cytokines and growth factor. The 
microenviroments surrounding the CSCs are termed as niche which modulates the cellular 
fate of the CSC [5-7].  
 CD44 is a multifunctional transmembrane glycoprotein which is a commonly used 
marker for isolating the CSCs from various cancers and mediating cell-cell and cell-matrix 
interactions furthering the malignancy and cancer dissemination. CD44 is typically 
associated with CD24, CD133, and CD34 for the enrichment of the various cancers. 
Hyaluronic Acid (HA) biosynthesis in the tumor microenvironment has been 
shown to increase the cancer aggressiveness and poor clinical outcome affecting the 
overall survival rate of the patients [8, 9]. Previous study with our platform of microarray 
showed that CD44 is overexpressed in all glioma cancer cell lines analyzed but little 
expressed in the normal adult brain and fetal brain [10]. In breast cancer cells, HA 
overexpression drives EMT which is one of the key aspects of the CSC generation and 
propagation [11]. Over recent years, CD44 along with other cell surface markers like 
CD133, CD90, CD24, ALDH, Nestin, EpCAM, and CD34 are also associated with CSC 
isolation and enrichment in various tumors [12]. In addition to its naturally occurring 
ligand, CD44 interacts with several ECM molecules including fibronectin galectin-8, 
laminin, fibrinogen, chondroitin sulfate and osteopontin [13, 14]. Since the principal 
ligand of CD44 is hyaluronan acid (HA), which is a major component of extracellular 
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matrices, CSC population was thought to be condensed by exploiting HA affinity toward 
CD44.  
In this study, U251MG and A172 cells were cultured under non-adherent condition 
in the presence of high molecular weight of hyaluronic acid (HA). The HA dependent 
spheroid forming population was then condensed and transplanted subcutaneously into 
Balb/c nude mouse. The primary cells excised from the resultant tumor were further 
characterized as CSC. (Figure 1)  
 
 
 
Figure 1: Scheme of glioma stem cell establishment mediated by HA. 1) Glioma cells line 
(U251MG / A172) were cultured in adherent plate until confluent. 2) Cell then transferred 
into non-coated dish supplemented with HA 3) 1x 104 / mL of cells were transferred into 
non-adherent dish for sphere culture with addition of HA 4) The resulting spheroids were 
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injected into nude mouse, where they generated malignant tumor. 5) The primary cells 
excised from the resultant tumor were culture in adherent dish until confluent 6) Prior to 
further characterized as CSC, cells were transferred into non- adherent dish to form 
spheres and were condensed with HA.  
 
2.0 Materials and Methods 
2.1 Cell culture 
 U251MG and A172 were cultured as per protocol decribed elsewhere [10].For 
primary cultures, mouse xenografts were cut into small pieces of 1 mm3 in HBSS. The 
tumor were further washed three times and were transferred to a 15-ml conical tube with 
0.25% trypsin (3-4 fold) for 30 min at 37°C and were stopped by the addition of media 
containing FBS. The cell suspension was spun down at 800 rpm for 10 min. The cell pellet 
was washed with HBSS and was suspended in complete media and seeded into a dish at a 
density of 5-6 ×105 cell /mL. Cells were passaged every 3 days and cells morphology was 
observed and photographed using Olympus IX81( Olympus, Japan) microscope equipped 
with a light flourescence device. 
 
2.2 Sphere Formation and HA treatments 
 
 For the sphere formation assay, the cell number were adjusted to 1× 104 /mL and 
were cultured in ultra-low attachment dishes in the media devoid of FBS and containing 
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Insulin/ Transferrin/ Selenium-X (ITS-X) and 100 µg/mL HA. The media without the 
supplementation of HA were included as a control. The cells were continued culturing for 
another 4 days and the spheres were distrupted to form secondary spheres for an additional 
culturing for 2 days. Spheres reaching 100 µm were considered as self-renewing and were 
used for all the analysis. 
 
2.3 Experimentals animal 
 
 The nude mice (Balb/c-nu/nu, female, 4 weeks old) were obtained from Charles 
River , Japan. For all the transplantation studies, 1×106  cells were suspended in 200 µL 
in complete media and were injected subcutenously . Size and volume measurement were 
done every 3-4 days with the following formula 0.5× width2×length, in which width is the 
smallest diameter and length is the longest diameter. After 5 weeks, tumors were extracted 
and separated in 4 equal parts that were used for the primary cell culture and histological 
analysis. The animals were maintained in dedicated animal facility in Okayama 
University . All the animal experiments conducted were carefully designed and executed 
as per general gudelines stipulated by the ethics committee of Okayama University. 
 
2.4 RNA Extraction and RT-qPCR 
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Total RNA was isolated by RNeasy Mini Kit (QIAGEN, Germany) and treated 
with DNase Amplification Grade (Invitrogen, CA). cDNA synthesis was performed using 
SuperScript III First strand kit (Invitrogen, CA). RT-qPCR was performed with Cycler 
480 SYBR Green I Master mix (Roche, Switzerland. The primers used for detect the 
cDNAs of interest are tabulated in Table 1.  
 
Table 1 : Primer sequences used in RT-qPCR analysis.  
Gene Sequence (5’-3’) 
Nanog 
F CAGCCCCGATTCTTCCACCAGTCCC 
R CGGAAGATTCCCAGTCGGGTTCACC 
OCT3/4 
F GACAGGGGGAGGGGAGGAGCTAGG 
R CTTCCCTCCAACCAGTTGCCCCAAAC 
Sox2 
F GGGAAATGGGAGGGGTGCAAAAGAGG 
R TTGCGTGAGTGTGGATGGGATTGGTG 
KLF4 
F ACGATCGTGGCCCCGGAAAAGGACC 
R TGATTGTAGTGCTTTCTGGCTGGGCTCC 
CD44s 
F AAGGAGCAGCACTTCAGGAG 
R GGACCAGAGGTTGTGTTTGC 
CD44v3 
F AAGGAGCAGCACTTCAGGAG 
R GGTCCAGTCCTGGTTCTGTT 
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CD44v4 
F AAGGAGCAGCACTTCAGGAG 
R GTGTGCTTCTGGGTTCCAGT 
CD44v6 
F AAGGAGCAGCACTTCAGGAG 
R CTGGGCTTGGTGTTGTCCTT 
CD44v8 
F AAGGAGCAGCACTTCAGGAG 
R TCTTCTTCCAAGCCTTCATGTG 
CD44v10 
F AAGGAGCAGCACTTCAGGAG 
R GATCCATGAGTGGTATGGGACC 
CD44 
v8-10 
F AAGGAGCAGCACTTCAGGAG 
R GGGTGGAATGTGTCTTGGTCT 
CD133 
F CGCGTGATTTCCCAGAAGATACT 
R ATACCCCACCAGAGGCATCA 
NFKB p105 
F CGGGAAAAAGAGCTAATCCGC 
R GATGCATTGGGGGCTTTACTG 
REL B 
F TGGATCCTGTGCTTTCCGAG 
R ACACCACTGATATGTCCTCTTTCT 
GAPDH 
F TGGTATCGTGGAAGGACTCA 
R CCAGTAGAGGCAGGGATGAT 
  *F : Forward primer; R : Reversed Primer 
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2.5 Cell Lysis and Western Blotting 
 
 Total cell extracts were collected as follows : Cells were lysed in 300 uL of lysis 
buffer (10 mM Tris-HCI, pH 7.5, 5 mM EDTA, 150 mM NaCI, 1% Triton -X 100, 10% 
(v/v) glycerol) containing protease inhibitor cocktail for 30 min at 4°C. The lysate was 
then sonicated for 30 secs; 2 times and were collected for the subsequent analysis. Cell 
extracts isolated were then subsequently separated in polyacrylamide gels, transferred 
onto PVDF membrane and incubated with specific antibodies as indicated. 
Immunoreactivity was revealed by chemiluminescense as per the manufacturer`s 
instructionand measured using the Atto imaging system (Atto, Japan).  
 
2.6 Immunohistochemistry and histological analysis 
 
 The tumor extracted from the animal were primarily fixed with paraformaldehyde 
for 24 h followed by paraffin embedding procedure for histochemical analysis. The fixed 
tissues was then thoroughly washed and were permeated with increasing concentration of 
sucrose. Tissue blocks were made with OCT reagent (Sakura-Finetek, Netherland) and 
were stored at-80°C until processing . The samples were fixed with absolute methanol for 
10 min followed by blocking of the endogenous peroxidase with 3% H2O2 for 10 min. 
Using the Ellite anti-rabbit ABC vectastain kit (Vector Laboratories, USA), anti -CD-31 
(1:100 , ab28364, Abcam, UK) and anti-CD133 (Novus Bio, USA), anti- LYVE-1 
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(Abcam,UK) antibodies were incubated for 2 hrs at room temperature. Immunoreactivity 
were detected by using DAB following the manufacturer`s recommendations. Images of 
the sections were processed with the FSX100 microscope (Olympus, Japan) for analysis 
and identification of the tumor type.  
 
3.0 Results and Discussion 
 
3.1 HA mediates enrichment of CD44 expressing population 
High molecular weight HA stimulates the CD44 mediated clustering of breast cancer 
cells [15]. The CD44 binding to HA also has various outcomes based on the size of HA 
binding to CD44 such as pro-angiogenic and pro-inflammatory while nHA promoted anti-
angiogenic and anti-inflammatory effects [16-18]. To assess the HA mediated enrichment 
of CD44, we cultured A172 and U251MG glioblastoma cells in both adherent and non-
adherent conditions at a concentration of 100 µg/mL of HA. The cells in the adherent 
conditions without HA were bound to the plate while the spheroids formation could be 
seen with the non-adherent HA+ treated cells (Figure 2A). The increment in the spheroid 
formation was further confirmed with culturing the A172 and U251MG with (HA+) and 
without (HA-) the addition of HA in the culture medium (Figure 2B).  
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Figure 2: Induction of A172 and U251MG cells with HA. A) Cell morphology of A172 
and U251MG cells on adherent and non-coated dish. B) Spheriod formation of A172 and 
U251MG cells in the presence or absence of HA for 2 weeks. 
 
 
 
A 
B 
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3.2 CD44 expression is upregulated by HA 
We next checked the expression of CD44 in A172, U251MG by qRT-PCR. The 
expression analysis was done between the cell lines treated with HA+ and HA- and 
between the adherent culture and non-adherent culture. In U251MG and A172 cell lines 
the CD44 expression was up regulated 3 folds in non-adherent HA+ cells when compared 
with adherent HA- counterpart (Figure 3A and 3B). The gene expression was further 
checked in the protein expression level through immunoblots with the cells. The 
immunoblot results clearly show that the HA-treated cells express more CD44 when 
compared to non-treated samples (Figure 3C). 
Figure 3 : Up regulation of CD44 expression in U251MG and A172. CD44 expression of 
adherent HA- and nonadherent HA+ treatment by qRT-PCR  of (A) U251MG and (B) 
29 
 
A172. (C) Protein expression was further confirmed with the various treatment in A172 
and U251MG cell;  A: Adherent, N: Non-adherent, H: Non-adherent HA+ . 
 
3.3 Generation of glioblastoma mouse model 
 
 
Using the HA-induced CD44 up regulation, we developed a glioblastoma mouse 
CSC model. We injected the spheres cultured of A172 and U251MG in the presence of 
HA into the mouse subcutaneously. However, tumor is not form in mouse injected with 
spheres cultured of A172 possibly because it is non-tumorigenic in immunosuppressed 
mice. In mice injected with spheroids cultured of U251MG, the tumor incidence time was 
faster in the [19]treated spheres within 40 days when the adherent culture injected mouse 
showed no signs of tumor formation substantiating tumor-initiating population in the HA 
cultured spheroids. HA-treated spheroids generated tumors faster in the mouse by several 
folds when compared with the cultures of U251MG cells cultured without HA in adherent 
conditions. Thus, the CD44 induction with the non-adherent conditions is found to be the 
deciding factor for the reduced tumor latency in the mouse (Figure 4A and B).  
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Figure 4 Characterization of mouse model of glioma . (A) Tumor formation in mouse 
with U251MG spheroids treated with HA and adherent culture of U251MG without the 
HA-culture 
HA-culture 
Adherent culture 
Adherent culture 
HA 
HA 
A 
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HA treatment. (B) Tumor incidence rate with spheroid/HA+ and adherent/HA- cultures 
of U251MG cells; n=2. 
 
3.4 Analyses of primary cells excised from the resultant tumor (U251MG-P1) 
compare with parental cell line (U251MG) 
 
3.4.1 Enrichment of spheroid forming population mediated by HA 
 
The primary cells excised from the tumor-bearing mouse were named as 
U251MG-P1. The U251MG-P1 showed enrichment of more spheroid forming population 
when compared with the parental cell line  (Figure 5A). The increment in the spheroid 
formation was further confirmed with culturing the U251MG-P1with (HA+) and without 
(HA-) the addition of HA in the culture medium (Figure 5B). The sphere formation was 
enhanced in U251MG-P1 resembling the stem cell morphology, while the parental cell 
line showed loosely formed aggregates with more differentiated cells.  
To test the self-renewal in the tumor spheroids generated by the treatment, we 
dissociated the cells to single cells suspension with collagenase treatment and were 
cultured for 2 weeks with HA in adherent conditions (Figure 5C). The cells retained the 
spheroid forming ability which resembles that of the CSCs. The presence of HA-CD44 
interaction in the cells promotes the aggregation and the CD44 over expressing population 
should be the reason for the reconstitution of the spheroid formation. The spheroid 
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formation and the incidence time for the sphere formation were up regulated with the 
treatment of HA. 
Figure 5 : Spheroid population in U251MG and U251MG-P1.A) Cell morphology of 
U251MG and U251MG-P1 on culture dish without HA and on non-coated dish with 100 
HA+ after 2 weeks Dissociated C 
HA+ HA- 
B 
A 
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µg/mL HA. Inset (red box) shows the magnified image of the spheroid formation of 
U251MG-P1 cells in non-coated dish with HA. B) Spheroid formation of U251MG and 
U251MG-P1 cells in the presence or absence of HA for 2 weeks. C) Cell morphologies of 
U251MG and U251MG-P1 after dissociation and culturing with HA for 2 weeks in 
adherent conditions.  
 
3.4.2 CD44 gene expressing  
 
We further compared the enrichment of the CD44 expression in the population of 
cells U251MG and U251MG-P1 in the adherent and spheroid conditions with and without 
the induction of HA The relative CD44 gene expression in U251MG and U251MG-P1 
cells were assesed using RT-qPCR . Relative expression of CD44 in cell lines treated with 
HA was up-regulated 2 fold for both cell when compared with adherent HA- conditions. 
All  results from these experiments proved that the CD44 expression is considerably up 
regulated by the treatment with HA there by the enrichment of the CD44 expressing 
population (Figure. 6A). We further analyzed the effect of CD44 isoform expression in 
U251MG and U251MP1cells. We found the expression of standard, V4, V8, V10 and V8-
10 to be up-regulated in U251MG-P1 (Figure. 6B). 
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Figure 6 : Relative CD44 gene expression in U251MG and U251MG-P1.A) U21MG and 
U251MG-P1 cells were cultured under adherent and non-adherent condition with or 
without the supplementation of HA. RT-qPCR was performed and relative expression fold 
of CD44 was calculated. B) ) Quantitative PCR analysis of the expression of CD44 
isoforms in U251MG and U251MG-P1 cells in adherent conditions. The data depicted are 
generated from two independent experiments. 
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3.4.3 HA induces the expression of pluripotent genes 
 
 
Aberrant activation of the pluripotent genes augments cancer initiation, 
progression, and chemotherapeutic resistance. These transcription factors are found to be 
over-expressed in several of the cancers and were used to identify cancer stem cell-like 
cells in glioblastoma [20]. HA-CD44 interaction was proved to activate Nanog which is 
principally involved in the stem cell maintenance and self-renewal in the ES cells [21-23]. 
The activation of CD44 through the PKCε phosphorylates Nanog, with or without the 
association of Stat3 regulates the expression of other pluripotent, tumorigenic and 
multidrug resistance genes [22]. Nanog has shown to regulate the expression of Sox2, 
Oct3/4, and Rex1, the prominent pluripotent transcription factors during ES cell 
pluripotency. To assess the activation of embryonic pluripotency genes, we performed the 
RT-qPCR for the various treatment of the cells in the conditions depicted in Figure 7. The 
cells treated with HA augments the expression of pluripotency genes suggesting the 
possible acquiring of stem cell characteristics (Figure 7A). Since Sox2 has been proved 
to be the principal pluripotency genes in the generation of CSC, we analyzed the 
expression further with immunoblots (Figure 7B). 
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Figure 7: Expression of pluripotent genes in U251MG and U251MG-P1 cells. (A) Cells 
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were cultured with or without HA in adherent or nonadherent conditions, RT-qPCR 
analysis was performed with the primers for Sox2, Oct3/4, Klf4 and nanog. Error bar 
represents the mean SD of two independent experiments. Data are the mean of 
independent experiments and the p values were calculated by Tukey HSD analysis 
(*p<0.05, **p<0.01; n=3). (B) Cells cultured under the different conditions were lysed, 
separated on SDS-PAGE and were immunoblotted for Sox2 expression. The normalized 
relative band intensity was calculated from the blot and were plotted as a graph using 
ImageJ. 
 
3.4.4 Activation of NFkB signalling in U251MG-P1 cells 
 
Activation of inflammatory and angiogenic mediators in U251MG-P1 cells NFκB 
complex activates MMP-9 and several other genes which are key response elements in the 
tumorigenesis and stem cell maintenance through tumor microenvironment mediated 
inflammation and ECM signaling [24-26]. To test the activation of inflammatory 
mediators we checked the NFκB activation in the HA-treated spheroids. NFκB activation 
has been associated with the mesenchymal subtype of the glioma and is proved to provide 
radioresistance in cancer [27]. We found that the HA induces p50/105 activation in the 
U251MG-P1 cells consistent with the results got from the high-grade glioblastoma models. 
Further, we found that p65 is activated in both parental and U251MG-P1 cells. Based on 
these observations we then checked for the genes involved in the NFκB family by 
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quantitative PCR and we found that the NFKB1, which is essential for the translocation 
of the p50/65 complex into the nucleus for the gene regulation, was suppressed, and REL-
B was found to be expressing in the U251MG-P1 cells showing the mesenchymal nature 
of the primary tumor cells (Figure 8). 
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Figure 8: Activation of inflammation and angiogenic mediators. (A) U251MG and 
U251MG-P1 were subjected to SDS-PAGE and were immunoblotted for p50/105 and p65. 
Beta actin was included as loading control for the experiment. Normalized band intensity 
were plotted as a bar graph using Image J (B) qPCR was performed with the designated 
primers in Table 1 (Material and method). 
 
3.5 Analysed of tumor tissue (U251MG-P1). 
3.5.1 Differentation marker (GFAP) and immunohistochemical analysis 
 
To evaluate the extent of differentiation in these tumors, the glial fibrillary acidic 
protein (GFAP), a marker used to distinguish astrocytes from glial cells which also is a 
progenitor marker for the neural stem cells (NSCs) were analysed. In our hands, the GFAP 
expression is reduced in the U251MG-P1 cells which might be due to the enrichment of 
the undifferentiated stem-like the population in the primary tumor from the mouse To 
further probe the stability of the GFAP expression in the tumor, we subsequently 
retransplanted the tumor to the mice and were further confirmed with the Western blot 
(Figure 9A). 
Immunohistochemical analysis showed the exend of angiogenesis induction along 
with the presence of CD133+ cells intercalated throughout the tumor. We further probed 
for the expression of LYVE-1 expression to check the lymphangiogenesis in the tumor 
and in our hands, the LYVE-1 expression was very much limited in the tumor . 
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Hispathological and gene expression analysis  have further confirmed the similar 
characteristic of the parental cancer cell lines (Figure 9B). 
Similar studies have been conducted in breast and colon cancer previously [19, 28] 
along with combining the genetic model with xenograft transplantations [29]. Similar 
studies has shown that the CD133+ conditioned media in glioma enhances the 
angiogenesis in patient xenografts in mouse by elevated VEGF expression and endothelial 
differentiation thereby the presence of stem cell populations determines the key events in 
angiogenesis and  vascular mimicry [30-32]. Similar model system was generated using 
miPS cells by our group where the angiogenesis/vascular mimicry were a cooperative 
interaction between the CSC and the microenvironment comprising of the differentiated 
populations, including the endothelial cells, and tumor stroma [33]. 
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Figure 9 : Characterization of the tumor in the mouse. (A) To check the extent of the 
differentiation in the tumor we compared the GFAP by western blotting in the parental, 
primary and secondary tumor culture in vitro. SK-OV-3 cell lysate was included as a 
negative control for the experiment. (B) Representative data for the immunohistochemical 
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analysis of the frozen tumor sections with anti-CD133, anti-CD31 and anti-LYVE-1 
antibodies. Scale Bar: 80 μm. 
 
4.0 Conclusion 
 
 
Xenograft models give more simultaneity and reproducibility with their high 
incidence of the tumor formation. Also they allow easy tumor visualization for the drug 
development process and efficient penetrance of the drug interactions with the tumor [34, 
35]. Enrichment of CD44 expressing cells would be a better platform in the drug targeting 
experiments for CSCs as we previously successfully showed targeting HER2 breast cancer 
cells with our bionanocapsule [36] and liposome [37, 38] with HER2-binding artificial 
ligands and such models will provide extensive knowledge in the therapeutic intervention 
in curbing the cancer growth and metastasis. The advantage of our model involves its cost-
effective enrichment of the CD44 expressing glioblastoma cells and high tumor incidence 
within a short time, enables us to study the effect of chemotherapeutic targeting. Further, 
the development of the mouse model will assist in the molecular targeting using anti-
CD44 antibody-drug encapsulated nanoparticles for glioma CSCs. 
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Chapter 3 
Targeting Glioblastoma Cells Expressing CD44 with Liposomes Encapsulating 
Doxorubicin and Displaying Chlorotoxin-IgG Fc Fusion Protein 
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LIST OF ABBREVIATIONS AND ACRONYMS 
 
 
BBB   Blood Brain Barrier 
CTX   Chlorotoxin 
CM   Conditioned media 
GBM   Glioblastoma Multiforme 
DAPI   4',6-diamidino-2-phenylindole 
DDS   Drug delivery systems 
DMEM  Dulbecco`s Modified Eagle`s medium 
Dox   Doxorubicin 
FBS   Fetal bovine serum 
E.coli   Escherichia coli 
HEPES  (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) 
h   hours 
hIgG-L-Dox  Liposome conjugated with human IgG encapsulating doxorubicin 
IC50   Half Maximal Inhibitory Concentration 
IgG   Immunoglobulin G 
IU   International Unit 
L-Dox   Liposome encapsulating doxorubicin without ligand 
nM   nanoMolar 
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nm   nanometer 
M-CTX-Fc  Chlorotoxin peptide fused to human IgG Fc region 
M-CTX-Fc-L-Dox Liposome conjugated with M-CTX-Fc encapsulating doxorubicin 
MMP-2  Matrix metalloprotease-2 
MLV   Multilamellar Vesicles 
min   minutes 
MTT   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
PBS   Phosphate Buffered Saline 
RES   Reticuloendothelial system 
RPMI   Roswell Park Memorial Institute medium 
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Abstract 
 
We recently have established a successful xenograft model of human glioblastoma 
cells by enriching hyaluronic acid-dependent spheroid-forming populations termed 
U251MG-P1 cells from U251MG cells. Since U251MG-P1 cells have been confirmed to 
express CD44 along with principal stemness marker genes, OCT3/4, SOX2, KLF4 and 
Nanog, this CD44 expressing population appeared to majorly consist of undifferentiated 
cells. Evaluating the sensitivity to anti-cancer agents, we found U251MG-P1 cells were 
sensitive to doxorubicin with IC50 at 200 nM. Although doxorubicin has serious side-
effects, establishment of an efficient therapy targeting undifferentiated glioblastoma cell 
population is necessary. We previously designed a chlorotoxin peptide fused to human 
IgG Fc region without hinge sequence (M-CTX-Fc), which exhibited a stronger growth 
inhibitory effect on the glioblastoma cell line A172 than an original chlorotoxin peptide. 
Combining these results together, we designed M-CTX-Fc conjugated liposomes 
encapsulating doxorubicin and used U251MG-P1 cells as the target model in this study. 
The liposome modified with M-CTX-Fc was designed with a diameter of approximately 
100–150 nm and showed high encapsulation efficiency, adequate loading capacity of 
anticancer drug, enhanced antitumor effects, demonstrating increasing uptake into the 
cells in vitro; M-CTX-Fc-L-Dox shows great promise in its ability to suppress tumor 
growth in vivo and it could serve as a template for targeted delivery of other therapeutics. 
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1.0 Introduction 
 
Glioblastoma  is a highly invasive cancer where the cells demonstrate their 
infiltrative growth to diffuse into the brain tissue [1]. This is the reason why the treatment 
of glioblastoma requires a multidisciplinary approach. Current standard of care for 
glioblastoma includes maximal safe surgical resection followed by radiotherapy and 
chemotherapy with alkylating agents, Temozolomide. The extensive and complete 
surgical treatment involves difficulties in glioblastoma with high degree of invasion 
because simultaneous removal of the surrounding normal areas will impair the function 
of brain controlling speech, motor function, sense and personality [2]. On that occasion, 
developing of brain tumor specific targeting drug delivery systems, which increase drug 
accumulation in the tumor region with less toxicity to the adjacent normal brain tissue, 
would significantly be a great approach for brain tumor treatments. The drug delivery to 
brain faces has been considered difficult as the agents need to across the blood brain 
barrier (BBB). However, recent study has shown that the tight junction of BBB loses the 
integrity by increasing permeability of the capillary endothelium [3]. 
On the other hand, recurrence of relapsing cancer is currently the central big issue 
to be studied. This is considered to occur due to the residual subpopulation of cancer cells 
after the treatment because they are believed to be resistant to the chemotherapy and 
radiotherapy even they are the minor population in the cancer tissues [4] . In this context, 
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chemical agents toxically effective to cancer cells should properly be chosen to design the 
effective drug delivery system. 
As for the efficacy of the drug delivery, targeting ability is another strong issue to 
be designed. Some cell surface antigens including receptors specific to gliomas and/or 
neovasculatures will be crucial markers to be targeted [5]. Hence, several approaches to 
treat brain cancer employ ligands specific to the tumor cells targeting the cell surface 
markers, which are overexpressed in cancer cells but low or not expressed in normal cells. 
Matrix metalloprotease-2 (MMP-2) is an extracellular matrix degrading enzyme, 
which play an important role in tumor invasion and is highly expressed in related cancer 
cells [6]. As for the MMP-2 in glioblastoma, the activity is increased along with the tumor 
grade and the expression is significantly higher than that in normal brain tissue. The 
increment is associated with the poor prognosis and overall short-life of survivors. MMP-
2 are secreted as an inactive zymogen and prior to its activation, it will bind to tissue 
inhibitor of metalloproteinase-2 associated with membrane type matrix metalloproteinase-
1, which localizes on the cell surface of the tumors [7, 8]. Membrane type matrix 
metalloproteinase-1 is replenished by auto degradation or clathrin-dependent 
internalization. Collectively, MMP-2 has been considered as a target for cancer therapy. 
Chlorotoxin (CTX) is a peptide derived from Egyptian scorpion venom, which has 
initially been characterized as a MMP-2 inhibitor and also as a voltage-gated chloride 
channel blocker [9, 10]. CTX exhibited high specificity, selectivity and affinity for glioma 
and other tumor of neuroectodermal origin [11]. Following the discovery, CTX has been 
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extensively developed as a ligand for active targeting to deliver cytotoxic agent, 
fluorescent dye for imaging and iodine for labeling to tumor cells [12-14]. Recent finding 
suggested that the delivery of CTX-modified liposome was mediated by MMP-2 but not 
correlated with the chloride channel CIC-3 when targeting U87 glioma cells [15].   
In our previous report, the CTX fused to human IgG Fc domain without hinge 
region in monomeric form (M-CTX-Fc) showed inhibition of mortality of glioma cell line 
A172 cells [16]. This inhibitory effect was enhanced when compared to the original CTX 
peptide. The similar effect was observed in pancreatic cancer cell PANC-1 cells [17]. 
Indicating M-CTX-Fc could be a potential ligand for active targeting of glioblastoma cells, 
the target-dependent internalization of bionanocapsules displaying M-CTX-Fc on the 
surface into cells was described [16].  
Very recently, we condensed the population overexpressing CD44 in U251MG 
cells exploiting the preferential affinity for hyaluronic acid as U251MG-P1 cells [18]. 
Since CD44 is well known as a common marker of cancer stem cells, we confirmed the 
expression of stemness markers as well as the tumor-initiating capacity in U251MG-P1 
cells  
In this study, we designed the liposomal drug delivery system of doxorubicin to 
evaluate the ability of M-CTX-Fc as an effective moiety to target glioblastoma cells 
expressing stemness markers using U251MG-P1 cells as the target model. 
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2.0 Materials and Methods 
 
2.1 Materials 
 
Dipalmitoylphosphatidylcholine (DPPC),1,2-distearoyl-sn-glycerol-3 
phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000] (mPEG–DSPE) and 1,2-
distearoyl-sn-glycerol-3-phosphoethanolamine-N-[maleimide (polyethylene glycol)-
2000] (Mal–PEG–DSPE) were obtained from NOF Co. (Tokyo, Japan). Cholesterol 
(Chol) was purchased from Kanto Chemical Co., Inc. (Tokyo, Japan). Thiazolyl blue 
tetrazolium bromide (MTT), 2-iminothiolane hydrochloride, human IgG, RPMI 1640 
medium, and DMEM were from Sigma-Aldrich (St Louis, MO, USA). Doxorubicin 
hydrochloride was purchased from Wako Pure Chemical (Osaka, Japan). Amicon Ultra 
filters were from Merck Millipore Ltd. (Billerica, MA, USA). PD-10 columns were from 
GE Healthcare (Carlsbad, CA, USA). 
 
2.2 Cell Cultures and Experimental Animals 
 
The human glioblastoma cell line A172 cells and human breast cancer cell line 
SK-BR-3 cells were obtained from ATCC (Manassas, VA, USA). U251MG-P1 was 
isolated from a xenograft tumor of human glioblastoma cell line U251MG cells in mouse 
[18]. A172 and U251MG-P1 were maintained in DMEM medium supplemented with 10% 
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fetal bovine serum (FBS) (PAA Laboratories, Pasching, Austria) in the presence of 100 
IU/mL penicillin and 100 μg/mL streptomycin (Nacalai Tesque, Kyoto, Japan). SK-BR-3 
cells were cultured in RPMI 1640 medium supplemented with 10% FBS in the presence 
of 100 IU/mL penicillin and 100 μg/mL streptomycin. Cells were cultured in a humidified 
incubator at 37°C with the atmosphere of 5% CO2. 
Four-week-old female BALB/c nude mice from Charles River (Kanagawa, Japan) 
were bred at 23 ˚C and fed with sterilized food and water during the experiments. All 
animal experimental protocols were reviewed and approved by the ethics committee 
known as IACUC (Institutional Animal Care and Use Committee) of Okayama University 
under project identification code OKU-2016078 (Date of approval :1 April 2016). 
 
2.3 Preparation of M-CTX-Fc 
 
M-CTX-Fc fusion protein was produced in our laboratory by recombinant 
expression in E.coli [14,15]. Briefly, M-CTX-Fc was expressed in E.coli as inclusion body 
and was refolded Escherichia coli BL21 (DE3) pLysS (Novagen) was transformed with 
expression vectors for M-CTX-Fcs. Transformants were grown in 1 L of LB medium 
containing 50 μg/mL kanamycin and 10 μg/mL chloramphenicol at 37 °C. Protein 
expression was induced by 0.4mM isopropyl 1-thio-β-D-galactopyranoside. After 
expression induction, the transformants were cultured at 25°C for 16 h, and the bacteria 
were harvested. Cell pellets were thawed and homogenized in 20mL of lysis buffer 
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containing 10mM Tris-HCl (pH 8.0), 10mM EDTA, 0.2M NaCl, and 10% sucrose. The 
inclusion bodies were collected by centrifugation at 12,000 × g for 20 min. 
 
 The inclusion bodies were washed three times with 0.5% Triton X-100. The 
insoluble fraction was resolved in 4 mL of 6M guanidinium HCl containing 0.1M Tris-
HCl (pH 8.5). The solution was degassed by aspiration while purging the air with nitrogen 
gas and supplemented with 50 μL of 2-mercaptoethanol. After 1 h incubation at 37°C in 
a shaking water bath, the mixture was dispersed into a 20-fold volume of refolding buffer 
containing 10mM Tris-HCl (pH 8.5), 0.1M NaCl, and 0.5mM oxidized glutathione. 
Refolding was conducted by incubation at 4 °C for 18 h. The pH was then adjusted to 7.0 
using acetic acid. Insoluble materials were removed by centrifugation at 12,000×g for 20 
min. The solution containing refolded protein was applied to a cobalt resin column 
(TALON superflow metal affinity resin, Clontech, Mountain View, CA, USA), after 
equilibrating with equilibration buffer containing 50mM phosphate buffer (pH 7.0) and 
300mM NaCl. The column was then washed with equilibration buffer containing 20mM 
imidazole and 0.1% Triton X-100. M-CTX-Fcs were eluted with elution buffer containing 
50mM phosphate buffer (pH 7.0), 300mM imidazole, and 300mM NaCl. The eluted 
solution was dialyzed three times against phosphate-buffered saline (Dulbecco’s formula, 
hereafter PBS) for 2 h each time. The purity of M-CTX-Fcs in the final preparations was 
assessed by SDS-PAGE, Coomassie Brilliant Blue (CBB) staining, and western blotting 
(Figure S1 in Supplementary Material). 
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2.4 Gelatin zymography for MMP-2 activity 
 
MMP-2 gelatinolytic activity in the CM was determined by zymography. Fifteen 
microliter aliquots of CM with or without M-CTX-Fc were subjected to 10 % SDS-PAGE 
containing 0.05% gelatine. The samples were prepared without reducing reagent and 
boiling prior to electrophoresis. After electrophoresis, the gel was washed twice in 2.5 % 
Triton X-100 for 30 min and once in 50 mM Tris-HCI, pH 7.4, 10 mM CaCl2 and 0.02 % 
NaN3. After incubation, gel was stained with Coomassie brilliant blue in 50 % methanol 
and 10 % acetic acid and destained in 10% methanol and 10% acetic acid. 
 
2.5 Preparation of liposomes encapsulating doxorubicin 
2.5.1  Encapsulation of doxorubicin into liposomes 
 
Liposomes composed of DPPC and chol with 5 mol% mPEG-DSPE were prepared 
by the thin-film hydration method followed by the transmembrane pH gradient method 
[19, 20]. In brief, DPPC, Chol, and mPEG-DSPE were dissolved in an organic solvent 
mixture consisting of chloroform and methanol (9:1, v/v) in a round-bottom flask 
equipped with rotary evaporator at 50˚C under aspirator vacuum. The resulting lipid film 
was left overnight under vacuum to ensure that all traces of organic solvent are removed 
from the film. Then, the film was hydrated with 300 mM citrate buffer, pH 4.0, by gentle 
mixing, resulting in spontaneously organized multilamellar vesicles (MLVs). MLVs were 
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freeze-thawed five times and passed through a Whatman polycarbonate membrane with a 
pore size of 100 nm (GE Healthcare, Carlsbad, CA) ten times using an extruder (Avanti 
Polar Lipids, Inc., Alabaster, AL) to form small, unilamellar vesicles. The liposome 
suspension was eluted using Sephadex G-25 (PD-10 desalting column) pre-equilibrated 
with PBS, pH 7.4, to form a pH gradient. Dox at pH 7.4 was introduced into the liposome 
suspension, and an excess of free Dox was removed by washing with PBS followed by 
ultrafiltration using a 100K-membrane filter. 
 
2.5.2 Preparation of M-CTX-Fc-L-Dox or hIgG-L-Dox 
 
The M-CTX-Fc or human IgG were coupling to liposome using classical method 
by employing the maleimide -thiol addition reaction [21]. Briefly, 2 mol% of Mal-PEG-
DSPE were incubated with Dox loaded liposome at 50 ˚C for 10 min. Simultaneously, 
thiol group (-SH) were introduced into M-CTX-Fc and human IgG by incubation with 
Traut’s reagent (2-iminothiolane) at molar ratio of 1:10 and 1:50 in 25 mM HEPES, pH 
8.0, containing 140 mM NaCI respectively. The reaction occurred under gentle stirring 
for 1 h in the dark at room temperature. Unreacted 2-IT reagent was removed by using gel 
chromatography G25 PD-10 column (GE Healthcare, Carlsbad, CA). Thiolated M-CTX-
Fc or human IgG was then coupled to Mal-PEG-DSPE by thioether linkage. The coupling 
reaction was performed overnight in the dark with gentle stirring at 4 ˚C. Free M-CTX-Fc 
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or human hIgG was removed by ultrafiltration with 100K and 300K membrane filter 
respectively (Sartorius Stedim Biotech GmbH, Gotttingen) (Figure S2). 
 
2.6 Characterization of liposomes 
2.6.1 Size distribution and zeta potential 
 
The size and zeta potential of liposomes were determined by dynamic and 
electrophoretic light scattering using an ELS-8000 (Photal Otsuka Electronic, Osaka, 
Japan).  
 
2.6.2 Encapsulation efficiency (EE) and loading efficiency (LE)  
 
The concentration of Dox was quantified by UV-VIS spectrophotometry (Corona 
Electric, Ibaraki, Japan) at 490 nm. EE was then calculated as the amount of drug loaded 
in the liposomes divided by initial amount of the drug. LE was calculated as the molar 
ratio of the drug loaded into liposomes to the total of lipid and Chol. 
 
2.7 Evaluation of cellular uptake of liposomes  
 
The cellular uptake of liposomes was evaluated according to the previously 
described method [15]. U251MG-P1 and SK-BR-3 cells were cultured on gelatin-coated 
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glass coverslips in a 12-well plate at a density of 3 x 105 cells per well for 24 h. Then, M-
CTX-Fc and L-Dox (containing Dox at 30 µg/mL) were added to a serum-free medium 
and incubated at 37 °C in the darkness for 1 h. The cells treated with a medium were used 
as a negative control. After the incubation, cells were washed three times with cold PBS 
and fixed with 4% paraformaldehyde for 20 min. After nuclear staining with DAPI 
(Vector Laboratories, Burlingame, CA), the fluorescent signal was imaged using a laser 
scanning confocal microscope (FV-1000, Olympus, Tokyo, Japan). 
 
2.8 Cytotoxic assay 
 
To investigate the in vitro cytotoxicity of various Dox-loaded liposomes in 
U251MG-P1 and SK-BR-3 cells, tetrazolium reduction assay was employed as previously 
described [22]. Briefly, 5,000 cells/well were seeded onto a 96-well plate and cultured for 
24 h. Then, the cells were incubated with 50 µL of a culture medium containing free Dox 
or different liposome formulations with various Dox concentrations for 72 h at 37 °C and 
5% CO2. Afterward, the cells were exposed to 5 mg/mL of MTT in PBS (the final 
concentration of 1 mg/mL) for 4 h. Formazan crystals formed during the incubation period 
were dissolved overnight at 37 °C by adding 10% SDS containing 20 mM HCI. The 
absorbance was measured at 570 nm using 96-well plate reader (Corona MTP-800, Tokyo, 
Japan). The exposure time required to kill 50% of the cells was evaluated as IT50, which 
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should be obtained at the minimum concentration of doxorubicin killing 100% of the cells 
after 72 h of exposure defined as IC100.  
 
2.9 Time- dependent cytotoxic effects 
 
 Time-dependent cellular cytotoxicity [22] was evaluated by the MTT assay with 
drugs at IC100 (Table 1). Briefly, U251MG-P1 and SK-BR-3 were seeded in a 96-well 
plate at 5 × 10 3 cell/well. After incubation at 37ºC under 5% CO2 for 24 h, drugs at each 
IC100 were added to each well and incubated for 1, 2, 6, 12, 24, 48, and 72 h. After each 
round of drug exposure, the medium was replaced with fresh medium without drugs and 
the incubation was continued until 72 h. Cell viability was determined by MTT assay. The 
time required for 50% growth inhibition (IT50) was estimated from the survival curve. 
Table 1. Cytotoxicity of different Dox formulations in U251MG-P1 and SK-BR-3 
 
U251MG-P1 SK-BR-3 
IC50 
(µM) 
IC100 
(µM) 
IT50 
(h) 
IC50 
(µM) 
IC100 
(µM) 
IT50 
(h) 
Dox 0.19 ± 0.11 1 2.3 ± 0.2 0.15 ± 0.02 1 3.0 ± 1.0 
L-Dox 0.35 ± 0.08 5 3.4 ± 0.4 0.21 ± 0.05 1 6.0 ± 0.8 
hIgG-L-Dox 0.66 ± 0.05 10 4.1 ± 0.6 0.38 ± 0.06 1 9.5 ± 0.6 
M-CTX-Fc-L-Dox 0.17 ± 0.07 1 1.6 ± 0.4 0.21 ± 0.04 1 6.6 ± 1.6 
IC50 and IT50 are presented as the mean ± S.D. (n = 3). 
IC100 was estimated from the evaluation of cytotoxicity. 
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2.10 Anti-tumor study in vivo 
 
The xenograft of U251MG-P1 cells in mice was prepared by a subcutaneous 
injection of 1 x 106 cells/mouse. Tumor volume was measured by a vernier caliper and 
calculated as [length x (width)2]/2. Anti-tumor effect of each formulation was evaluated 
when the tumor volume reached 100-200 mm3. Mice were randomly assigned to five 
groups (n = 3); group 1 for saline, group 2 for naked Dox, group 3 for L-Dox, group 4 for 
hIgG-L-Dox and group 5 for M-CTX-Fc-L-Dox. Ten mg of doxorubicin per kg body 
weight was injected three times via tail vein at the intervals of 7-day. Tumor volume was 
measured every three days. 
 
2.11 Statistical analysis 
 
All the experiments were at least three-time repetition. Data were depicted as 
means ± standard deviation. The statistical significance in mean values between two 
groups was determined by 2-tailed student`s t-test. The statistical significance between the 
mean values of more than two groups was determined using one-way analysis of variance 
(ANOVA) and post hoc Tukey HSD. A p-value less than 0.05 was considered to be 
statistically significant, and a p-value less than 0.01 was regarded as highly significant. 
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3.0  Results and Discussion 
3.1 Sensitivity of U251MG-P1 Cells to Doxorubicin 
 
First of all, we assessed the effect of doxorubicin on U251MG-P1 cells (Figure 1). 
We chose doxorubicin as the first priority because the liposomal formulation is well 
established by pH gradient and ammonium sulfate gradient method and has clinically been 
tested in the glioblastoma cancer therapy [23, 24]. As the result, MTT assay showed the 
IC50 at around 200 nM, which was a feasible concentration available as an agent for cancer 
chemotherapy. 
 
Figure 1. The U251MG-P1 cells are sensitive to doxorubicin. Cytotoxicity of 
doxorubicin was assessed on U251MG-P1 cells by MTT assay. The data presented as 
the mean ± S.D (n=3) from independent experiment. 
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However, cardiotoxicity is the well-known side effect of doxorubicin, so that the 
amount of administration through the lifetime is critically limited. If doxorubicin is one 
of the rare candidates of effective agents to treat such as cancer stem cells, the 
development of drug delivery system to avoid the side effects should seriously be 
important. 
 
3.2. Expression of MMP-2 in U251MG-P1 cells 
 
We assessed the expression of MMP-2 in U251MG-P1 cells to confirm that MMP-
2 could be a sufficient marker to target the cells. A172 (MMP-2 positive) and human 
breast cancer SK-BR-3 (MMP-2 negative) cell line by both Western blot and reverse 
transcription-polymerase chain reaction (qRT-PCR) as shown in Figure 2A, 1B, and 1C. 
The 72 kDa protein treated with anti-MMP2 antibody corresponding to proMMP-2 was 
observed in U251MG-P1 and A172 but less or not seen in SK-BR-3. Since U251MG-P1 
cells were confirmed to express the MMP-2, we decided to employ CTX for the specific 
ligand to target U251MG-P1 cells. 
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Figure 2: The U251MG-P1 cells are expressing MMP-2. A) Western blot of cells with 
anti-MMP-2 and anti-beta-actin antibodies, B) Relative intensity of the bands in Western 
blot densitometrically analyzed by ImageJ. C) Relative gene expression analyzed by 
reverse transcription quantitative PCR. The data presented as the mean ± S.D (n=3) from 
three independent experiments. The data were analyzed by 2-tailed students t-test using 
A172 cells as a control; *, P<0.05; **, P<0.01; ***, P<0.005; ****, P<0.001. NSD, no 
significant difference 
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3.3. Characterization of M-CTX-Fc 
 
Peptide ligands specific to cell surface molecules have extensively been used for 
various drug delivery targeting cancer cells. However, they are often labile and degraded 
resulting in short half-life due to their antigenicity and reticuloendothelial system (RES) 
[25]. One of the approaches to overcome those problems is to fuse the ligand with human 
IgG Fc domain. The Fc domain provides significant advantages such as to improve the 
solubility and stability of partner molecule and to prolong the half-life in plasma [26, 27] .  
After preparation of M-CTX-Fc from E.coli, the ability to inhibit the gelatinase 
activity of secreted MMP-2 in the condition medium of U251MG-P1 cells was observed 
by gelatin zymography (Figure 3A). The intensity of gelatinase activity decreased in the 
presence of M-CTX-Fc in a dose-dependent manner. This confirmed us the interaction of 
M-CTX-Fc with MMP-2 even though the exact molecular target of CTX still unknown 
[28]. We then evaluated the activity of M-CTX-Fc on the proliferation and viability of 
U251MG-P1 cells. M-CTX-Fc suppressed the growth of the cells as describe in another 
cells such as glioma cell line A172 cells and pancreatic canrcinoma cell line Panc-1 cells 
[16,17] (Figure 3B and C). This cell growth inhibition does not appear inducing cell 
death because the cell viability recovered after removal of the protein from the culture 
medium while CTX alone did not affect the cell growth of U251MG-P1. Collectively, we 
concluded that M-CTX-Fc is folded properly.  Hence, we chose M-CTX-Fc in place of 
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CTX as the ligand to target U251MG-P1 cells considering the Fc moiety would help the 
conformation of CTX intact when conjugated on the surface of liposome.  
 
 
Figure 3. M-CTX-Fc inhibits gelatinase activity in the condition medium of U251MG-
P1 cells (A) and cell growth of U251MG-P1 cells (B and C). The M-CTX-Fc inhibit 
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gelatinase activity. A) MMP-2 activity in the condition medium of U251MGP1 cells was 
monitored by zymography in the presence of 0, 60, 120, and 240 nM of M-CTX-Fc. The 
data presented as the mean ± S.D (n=3) from technical replicates. The statistical 
significance in mean values of more than two groups was determined using one-way 
analysis of variance (ANOVA) and post hoc Tukey HSD were applied using CM without 
M-CTX-Fc as control *, P<0.05; **, P<0.01; ***, P<0.005; ****, P<0.001. NSD, no 
significant difference. B) The inhibition of cell growth in the presence of M-CTX-Fc and 
CTX after 48 h. C) The viable cells at 48 h were kept cultured without M-CTX-Fcs or 
CTX up to 72 h. Cell numbers in each well were assessed by MTT assay. The absorbance 
at 570 nm corresponding to the initial number of the cells was defined as 1.  The data 
presented as the mean ± S.D (n=3) from three independent experiments. The data were 
analyzed by 2-tailed students t-test using M-CTX-Fc as a control; *, P<0.05; **, P<0.01; 
***, P<0.005; ****, P<0.001. NSD, no significant difference 
 
3.4. Characterization and optimization of M-CTX-Fc conjugated to liposome. 
 
Prior to further investigation of their cytotoxicity in vitro and in vivo, we optimized 
the amount of M-CTX-Fc (nmol) conjugated to liposome. The preparation of liposomes 
conjugated with M-CTX-Fc encapsulating doxorubicin (M-CTX-Fc-L-Dox) is 
summarized in Figure 4A. Various amount of M-CTX-Fc such as 5 nmol, 10 nmol, 15 
nmol or 20 nmol conjugated to liposome encapsulating doxorubicin was prepared, 
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respectively. The mean particle size of these liposome were almost 150 nm, which was 
not significantly affected by the amount of ligand as previously described [29, 30]. The 
optimal amount of M-CTX-Fc conjugated to liposome was determined by the IC50 (Figure 
4B). When 10 nmol of M-CTX-Fc were used to conjugate to liposome, the cytotoxicity 
of doxorubicin was the maximum whereas 5 nmol was not enough for binding with 
receptor. Similarly, M-CTX-Fc  at 15 nmol and 20 nmol did not improve the cytotoxic 
effect of liposome encapsulating doxorubicin. We further investigated the capability of 
specific targeting of liposome by using M-CTX-Fc at 10 nmol. 
The characteristics of the formulations of liposomes encapsulating doxorubicin 
used in this study were summarized in Table 2. The liposomes conjugated with human 
IgG (hIgG-L-Dox) or without ligands (L-Dox) were prepared as references of nonspecific 
targeting. All the prepared liposomes showed diameters approximately 150 nm with low 
polydispersity index less than 0.1 indicating homogeneous uniformity. The uniformity of 
particle size is considered important to obtain the stable receptor-mediated endocytosis in 
the intracellular delivery by the nano-carrier system [31]. The particle size between 50 
and 200 nm is considered sufficient to accumulate the drug in the tumor via enhanced 
permeability and retention (EPR) effect since particles with larger size are generally 
trapped by the RES resulting in short half-life by rapid clearance from blood flow [32].  
Tranmission electron microscopy (TEM) revealed that all the formulation of 
liposome encapsulating doxorubicin exhibited precipitates of fibrous-bundle aggregates 
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when doxorubicin was encapsulated into the inner core of liposome the loading method 
of pH gradient (Figure 5) [19]. 
 
Figure 4. The amount of M-CTX-Fc  conjugated to liposomes encapsulating doxorubicin 
was optimal at 10 nmol / 48 µmol DPPC. (A) Conjugation procedure of M-CTX-Fc to 
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liposomes encapsulating doxorubicin. (B) IC50 of doxorubicin encapsulated in liposomes 
conjugating various amount of M-CTX-Fc) against U251MG-P1 cells. The data presented 
as the mean ± S.D (n=3) from independent experiments. The statistical significance in 
mean values of more than two groups was determined using one-way analysis of variance 
(ANOVA) and post hoc Tukey HSD were applied using no M-CTX-Fc (0 mol) as control. 
*, P<0.05; **, P<0.01; ***, P<0.005; ****, P<0.001. NSD, no significant difference. 
 
Table 2. Characteristics of the formulations of liposomes encapsulating doxorubicin 
Formulations Diameter 
(nm) 
Polydispersity 
index 
Zeta 
potential (-
mV) 
Encapsulation 
Efficiency (%) 
Loading 
Efficiency 
(%) 
L-Dox 133.4 ± 12.7 0.09 ± 0.03 8.13 ± 2.32 97.5 ± 3.1 3.4 ± 0.1 
M-CTX-Fc-L-
Dox 
148.3 ± 3.0 0.05 ± 0.03 7.86 ± 1.19 98.2 ± 1.3 4.5 ± 0.4 
hIgG-L-Dox 151.3 ± 4.3 0.07 ± 0.02 6.66 ± 3.78 94.4 ± 7.2 4.1 ± 0.4 
Each experiment was performed in triplicate and the values are given as mean ±SD.  
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Figure 5: M-CTX-Fc-L-Dox showed unilamellar vesicles with diameter of 
approximately 100 nm. TEM images of liposome formulation encapsulating doxorubicin 
were compared between M-CTX-Fc-L-Dox, hIgG-L-Dox and L-Dox. Each scale bar 
shows 100nm. 
 
3.5 Cellular uptake of liposomes 
 
The cellular uptake of M-CTX-Fc-L-Dox and L-Dox into U251MG-P1 and SK-BR-
3 cells was evaluated under a confocal microscope after 1 h incubation at 37°C (Figure 6). 
It is worth noting that the strong fluorescence of doxorubicin was observed in U251MG-
P1 cells treated with M-CTX-Fc-L-Dox, especially in the nuclei. This observation might 
be attributed to the specific interaction of M-CTX-Fc-L-Dox with the cell surface 
molecule on U251MG-P1 cells by receptor-mediated endocytosis. On the other hand, 
when cells were treated with L-Dox, the fluorescence from L-Dox was reduced compared 
to that from M-CTX-Fc-L-Dox. It is important to mention that receptor-mediated 
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endocytosis achieved by M-CTX-Fc-L-Dox might be faster than the endocytosis gained 
by L-Dox only. This explanation agrees with our result for IT50 in figure 7. Oppositely, 
almost no signal for doxorubicin uptake was observed in the SK-BR-3 cells, which 
showed low expression of MMP-2 compared to U251MG-P1 cells. Collectively, M-CTX-
Fc may have the potential to target MMP-2 expressing cancer cells and internalize into 
the cells while further investigation is required to identify the molecule on the cell surface 
directly binding to M-CTX-Fc.  
 
 
Figure 6. Cellular uptake of Doxorubicin in U251MG-P1 cells was enhanced through 
M-CTX-Fc-L-Dox. U251MG-P1 cells and SK-BR-3 cells were evaluated for the 
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cellular uptake of doxorubicin under a confocal microscope. Cell nuclei were stained 
with DAPI (blue). Red color arises from natural fluorescence properties of 
doxorubicin. Each scale bar shows 50 µm. 
 
 
3.6 Cytotoxicity In Vitro 
 
 
The IC50s of doxorubicin were assessed when U251MG-P1 and SK-BR-3 cells were 
treated for 72 h with each formulation of naked doxorubicin, L-Dox, M-CTX-Fc-L-Dox 
and hIgG-L-Dox (Figure 7). Among the liposomal formulations, M-CTX-Fc-L-Dox 
showed the highest cytotoxicity with the lowest IC50 of 0.17 µM in U251MG-P1 cells. 
However, the cytotoxicity of M-CTX-Fc-L-Dox showed no significant different with 
naked doxorubicin. In SKBR-3 cells without MMP-2 expression, M-CTX-Fc-L-Dox 
appeared almost equally effective with hIgG-L-Dox and L-Dox. Collectively, the results 
appear consistent with the dependency of MMP-2 expression. As described previously, 
we thought the time of exposure allowing the cellular uptake should also be important to 
determine the effectiveness [22]. To make this point clearer, we evaluated the IT50s.  
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In U251MG-P1 cells, M-CTX-Fc-L-Dox showed significantly rapid exposure time of 
IT50 at around 1.6 h. This is the shortest time when compared with those by other 
formulations. Meanwhile, in both cells, naked doxorubicin had rapid exposure time 
compared to L-Dox. This result could be explained by the difference of cellular 
mechanism of internalization. The cellular uptake of liposome is mediated by endocytosis, 
whereas the naked doxorubicin molecules internalized into the cell via passive diffusion. 
However, in the case of M-CTX-Fc-L-Dox, the conjugated ligand specific to MMP-2 
receptor, exhibited shorter time for liposomes internalized into the cells and reaches IT50 
comparable to the naked doxorubicin. On the other hand, in SK-BR-3 cells, no significant 
difference was found between L-Dox and M-CTX-Fc-L-Dox. Thus, M-CTX-Fc-L-Dox 
successfully demonstrated the specific targeting of U251MG-P1 cells in vitro. 
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Figure 7: M-CTX-Fc-L-Dox exhibited the lowest inhibition concentration (IC50) and 
shortest exposure time (IT50) in U251MG-P1 cells. In vitro cytotoxicity IC50 of 
doxorubicin in different formulations after 72 h of exposure to U251MG-P1 and SK-
BR-3 cells was evaluated and compared (top). IT50s with doxorubicin at IC100 were 
evaluated and compared (bottom). The data presented as the mean ± S.D (n=3). The 
statistical significance in mean values of more than two groups was determined using 
one-way analysis of variance (ANOVA) and post hoc Tukey HSD were applied using 
M-CTX-Fc-L-Dox liposome as control. *, P<0.05; **, P<0.01; ***, P<0.005; ****, 
P<0.001. NSD, no significant difference. #, P<0.05 versus Dox. 
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3.7 Suppression of tumor growth In Vivo 
 
The suppression of tumor growth by M-CTX-Fc-L-Dox was evaluated in BALB/c 
mice bearing tumors of transplanted U251MG-P1 cells (Figure 8). We found that the 
tumor latency of U251MG-P1 is so rapid that it should not be comparable with that of 
U251MG cells. Meanwhile, the tumor latency of U251MG is not stable. This means that 
the targeting effect of our liposomal formulation is difficult to be demonstrated on the 
tumors from U251MG cells. First of all, the effect of doxorubicin on the body weight was 
assessed by the three-time injections of 10 mg/kg (Figure 8A). As the result, the loss of 
body weight was less than 20 % even when the naked doxorubicin was injected. The 
liposomal formulations were less toxic than naked doxorubicin as they showed body 
weight loss less than 10 %. After three times of injection in seven-day intervals, the tumor 
growth was observed for 20 days, and the efficacy of the suppression of tumor growth was 
calculated as a relative tumor volume normalized to the initial tumor volume before the 
treatment. The tumor volume in the PBS group increased aggressively, whereas M-CTX-
Fc-L-Dox slowed the tumor growth more significant than naked Dox and hIgG-L-Dox at 
day 20 (p<0.001) (Figure 8B). M-CTX-Fc-L-Dox appeared slightly more effective than 
L-Dox at day 20 (p = 0.043<0.05). The representative tumors excised from the mice 
treated with five different formulations at day 20 demonstrated tumor suppression effect 
of M-CTX-Fc-L-Dox (Figure 8C). In this context, M-CTX-Fc-Dox exhibited an 
inhibitory effect on tumor growth, which could be attributed to the combined action of the 
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passive targeting via the EPR effect and active targeting via receptor-mediated 
endocytosis. However, a larger cohort-evaluation is needed to confirm the effect of M-
CTX-Fc-L-Dox more precisely 
 
 
Figure 8: M-CTX-Fc-L-Dox suppressed tumor growth in the most effective manner in 
vivo. (A) The relative body weight of mice bearing tumors during the treatment. M-CTX-
FC-L-Dox and other liposome formulations were less toxic than naked doxorubicin. The 
statistical significance in mean values of more than two groups was determined using one-
way analysis of variance (ANOVA) and post hoc Tukey HSD were applied using relatives 
body weight of Dox treatment as control. ****, P<0.001. (B) The effect of different 
84 
 
formulations of doxorubicin on the volume of tumors. M-CTX-Fc-L-Dox was the most 
effective formulation to suppress the growth of tumor. Doxorubicin in each formulation 
was administered at 7- day intervals vertical arrows. The statistical significance in mean 
values of more than two groups was determined using one-way analysis of variance 
(ANOVA) and post hoc Tukey HSD were applied using relatives’ tumor volume of M-
CTX-Fc-L-Dox treatment as control, *, P<0.05; ****, P<0.001 (C) The tumors from the 
experiment (B) representing each group were displayed exhibiting the effect of each 
formulation of doxorubicin. Data are expressed as the mean with ±SD where n=3. 
 
 
4.0 Conclusions 
 
In our previous study, the U251MG-P1 cells has shown the CD44 expression was 
enriched when  compared to the parental U251MG cells, along with aberrant activation of 
principal stemness marker genes OCT3/4. SOX2, KLF4 and Nanog and with less 
expression of glial fibrillary acidic protein . This  mean U251MG-P1 cells consist of rather 
undifferentiated cells than the parental U251MG cells. Additionally, U251MG-P1 cells 
are highly tumorigenic exhibiting rapid tumor growth in vivo, when compared to 
U251MG cells. This high tumorigenicity enabled us to study the drug delivery in vivo. 
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Drug delivery targeting cancer cells derived from glioblastoma was successfully 
demonstrated in vitro and in vivo with chlorotoxin fused to human IgG Fc domain in this 
study. As the results, chlorotoxin fusion protein shortened the IT50 of doxorubicin 
encapsulated in liposomes in vitro and suppressed the growth of tumor in vivo when 
compared with the liposomes without chlorotoxin ligand. Although we could not show 
the direct binding of M-CTX-Fc to MMP-2, we could show significant difference in the 
relative tumor growth between the treatment with M-CTX-Fc-L-Dox and that with L-Dox 
at day 20 (P< 0.05) This difference appeared to depend on the expression of MMP-2 
according to the previous report, which demonstrated the specific interaction of 
chlorotoxin and MMP-2 [10].Thus, the combination of doxorubicin and chlorotoxin is 
proposed in this paper as a successful candidate of liposomal DDS formulation to target 
possibly glioblastoma stem cells and derivative tumor. 
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5.0 Supplementary data 
 
 
Figure S1. M-CTX-Fc in reducing and nonreducing conditions. Purified protein was 
subjected to SDS-PAGE and detected by CBB staining (left) and Western blotting with 
mouse monoclonal anti-human IgG antibody (right) as monomer at approximately 30 
kDa. 
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Figure S2. Dot blotting analysis of liposomes conjugated to ligands. Liposomes 
containing approximately 1 µg of doxorubicin in 3 µL were blotted onto PVDF membrane 
(A) and probed with mouse monoclonal anti-human IgG antibody conjugated with HRP 
(B). The immunoreactivity indicates the successful conjugation of M-CTX-Fc and hIgG 
to liposomes. 
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